<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02359500</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 14-2008</org_study_id>
    <nct_id>NCT02359500</nct_id>
  </id_info>
  <brief_title>68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)</brief_title>
  <official_title>Safety and Efficacy Study of 68Ga-Dotatoc Positron Emission Tomography for Diagnosis for Staging, Restaging and Assessment of Response to Treatment in Somatostatin Receptor-Positive Neuroendocrine Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lale Kostakoglu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study plans to demonstrate the safety and efficacy of [68Ga]-DOTA-tyr3-Octreotide&#xD;
      ([68Ga]-DOTATOC) as an accurate imaging technique for diagnosis, staging, and monitoring of&#xD;
      response to treatment in patients with Somatostatin receptor expressing tumors who undergo&#xD;
      imaging with a clinical indication. The investigators will conduct a study for 68Ga-DOTATOC&#xD;
      as a diagnostic PET/CT imaging agent for the detection of NETs, mainly carcinoid tumors.&#xD;
      68Ga-DOTATOC will be used in diagnostic assessment of patients with known or suspected NETs&#xD;
      for whom there is an appropriate standard clinical indication for 68Ga-DOTATOC PET/CT either&#xD;
      at staging or during follow up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale and overall study design This study is planned to demonstrate the safety and&#xD;
      efficacy of [68Ga]-DOTA-tyr3-Octreotide ([68Ga]-DOTATOC) as an accurate imaging technique for&#xD;
      diagnosis, staging, and monitoring of response to treatment in patients with Somatostatin&#xD;
      receptor expressing tumors who undergo imaging with a clinical indication.&#xD;
&#xD;
      Neuroendocrine tumors (NET) are rare neoplasms of neuroendocrine origin. Neuroendocrine&#xD;
      tumors are solid malignant tumors that arise from dispersed neuroendocrine cells found&#xD;
      throughout the body. They are well known for their heterogeneity which makes it difficult to&#xD;
      obtain uniform clinical data and establish universal guidelines for the diagnosis and&#xD;
      treatment of NETs. NETs are characterized by overexpression of somatostatin receptors, which&#xD;
      can be visualized and targeted by radiolabeled somatostatin analogues.&#xD;
      111In-diethylenetriaminepentaacetic acid-octreotide scintigraphy (111In-Octreotide) with&#xD;
      single photon emission tomography (SPECT) is currently the standard imaging modality for&#xD;
      evaluating patients with NETs. 111In Octreotide is the only FDA approved radiopharmaceutical&#xD;
      available on the market for assessing the extent of involvement by NETs at both staging and&#xD;
      follow up periods. However, the sensitivity of this imaging modality is lower compared to the&#xD;
      positron emission tomography (PET) radiotracer 68Ga-DOTA0-Tyr3]octreotide (68Ga-DOTA-TOC).&#xD;
      Based on the improved sensitivity, 68Ga DOTATOC PET leads to significant changes in 30% of&#xD;
      patients. Importantly, the radiation exposure of 68Ga-DOTATOC PET is lower than that of 111In&#xD;
      Octreotide and also the imaging with 68Ga-DOTATOC PET scan yields fast read-outs on the same&#xD;
      day compared to 24-48 hour read-outs with 111In Octreotide scan. These advantages make the&#xD;
      68Ga labeled somatostatin analog more attractive from both the patient and management&#xD;
      perspectives. The improved resolution and quantitation of uptake obtained with Ga-68 DOTATOC&#xD;
      PET should provide a more accurate assessment of somatostatin receptor density, which will&#xD;
      lead to a more accurate prediction of treatment response to somatostatin analogues.&#xD;
&#xD;
      While the investment costs for the scanner, the radiochemistry equipment are higher for&#xD;
      68Ga-DOTATOC PET/CT compared with 111In-DTPA-octreotide scintigraphy and SPECT, with the&#xD;
      provision of this imaging molecule by an established commercial radiopharmaceutical company&#xD;
      that in with compliance to FDA 21 CFR Part 212 IBA Molecular Inc, NJ, USA, this will not pose&#xD;
      a limitation for the Mount Sinai Medical Center. In this setting, 68Ga-DOTATOC PET/CT&#xD;
      production and personnel costs will be borne by the commercial entity, however, Mount Sinai&#xD;
      Medical Center will purchase the 68Ga-DOTATOC based on a per patient schedule. Since this&#xD;
      imaging modality does not have a quote for reimbursement by the insurance carriers, the&#xD;
      imaging cost is considered a potential burden on the patient until it is approved by the U.S.&#xD;
      Food and Drug Administration (FDA). There is significant amount of European based clinical&#xD;
      data (&gt;1000 patients) to prove the safety and efficacy of this imaging agent, therefore, a&#xD;
      phase II or III clinical trial in the US is redundant and will only delay the approval of&#xD;
      this imaging probe. Recently, Ga-68 DOTATOC has been designated as an orphan drug by the FDA&#xD;
      for the management of NET. This designation will probably lead to faster approval of the&#xD;
      agent, which would greatly benefit NET patients in the US. Currently, there are only several&#xD;
      small U.S.-based clinical trials for Ga-68 labeled NET PET agents available for patients;&#xD;
      otherwise they must travel out of the country if the scan is required to manage their&#xD;
      disease.&#xD;
&#xD;
      The investigators, therefore, aim to provide this superior imaging technique to NET patients&#xD;
      for better disease management by the referring physicians, however, this objective cannot be&#xD;
      attained unless at least a partial funding mechanism exists to make it affordable by the&#xD;
      patients until the approval of this superior imaging probe. In this regard, the investigators&#xD;
      are aiming at recovering the cost of the radiotracer from the local insurance carrier through&#xD;
      the cost recovery system.&#xD;
&#xD;
      Participant Enrollment Participants will be recruited from the Mount Sinai Medical Center.&#xD;
      Participants who will be approached regarding the study are those individuals who are being&#xD;
      seen for known or suspected malignancies.&#xD;
&#xD;
      Patients may remain on their somatostatin therapies throughout the study with no management&#xD;
      change merely based on the 68Ga -DOTATOC PET/CT imaging findings. The management of these&#xD;
      patients will be based on the standard of care and any change will be at the discretion of&#xD;
      the referring physician. All pertinent dosing information must be collected and reported.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    compound no longer available&#xD;
  </why_stopped>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">January 23, 2017</completion_date>
  <primary_completion_date type="Actual">January 23, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in size of lesion</measure>
    <time_frame>baseline and 1 month</time_frame>
    <description>Change in size of lesion at 1 month as compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of new lesions</measure>
    <time_frame>baseline and 1 month</time_frame>
    <description>Number of new lesions at 1 month as compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of change in treatment</measure>
    <time_frame>baseline and 1 month</time_frame>
    <description>Change in treatment caused by result of 68Ga-DOTATOC PET/CT at 1 month as compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of previously unknown primary tumor</measure>
    <time_frame>baseline and 1 month</time_frame>
    <description>Incidence of identification of the location of a previously unknown primary tumor at 1 month as compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <condition>Carcinoid Tumors</condition>
  <arm_group>
    <arm_group_label>68Ga-DOTATOC PET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with known or suspected somatostatin receptor positive neuroendocrine tumors (NETs)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68Ga-DOTATOC PET</intervention_name>
    <description>68Ga-DOTATOC as a diagnostic PET/CT imaging agent for the detection of NETs, mainly carcinoid tumors.</description>
    <arm_group_label>68Ga-DOTATOC PET</arm_group_label>
    <other_name>[68Ga]-DOTA-tyr3-Octreotide</other_name>
    <other_name>[68Ga]-DOTATOC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Known or suspected somatostatin receptor positive NETs (e.g. carcinoid, pancreatic&#xD;
             neuroendocrine tumors, and pheochromocytoma). Supporting evidence may include MRI, CT,&#xD;
             biochemical markers, and or pathology report.&#xD;
&#xD;
          -  Karnofsky performance status of â‰¥50 (or ECOG/WHO equivalent)&#xD;
&#xD;
          -  Off Sandostatin (octreotide acetate)-long acting release (LAR) &gt; 4 weeks and off&#xD;
             immediate release (subcutaneous) for at least 12 hrs prior to 68Ga-DOTATOC PET-CT&#xD;
             imaging&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breast feeding. A negative serum pregnancy test is required for all&#xD;
             female subjects with child- bearing potential&#xD;
&#xD;
          -  Surgical resection, chemotherapy, radiation therapy, or biologic therapy since last&#xD;
             Octreoscan + CT; continuation of the same dose of Sandostatin-LAR or subcutaneous&#xD;
             Sandostatin is allowed&#xD;
&#xD;
          -  Medical condition uncontrolled by treatment making completion of study unlikely&#xD;
&#xD;
          -  Patients exceeding the weight limitations of the scanner or are not able to enter the&#xD;
             bore of the PET/CT scanner due to Body Mass Index (BMI)&#xD;
&#xD;
          -  Inability to complete the needed investigational and standard-of-care imaging&#xD;
             examinations due to other reasons (e.g. severe claustrophobia)&#xD;
&#xD;
          -  Any additional medical condition, serious intercurrent illness or other extenuating&#xD;
             circumstance that, in the opinion of the Investigator, may significantly interfere&#xD;
             with study performance or interpretation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lale Kostakoglu, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>January 23, 2015</study_first_submitted>
  <study_first_submitted_qc>February 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2015</study_first_posted>
  <last_update_submitted>May 1, 2017</last_update_submitted>
  <last_update_submitted_qc>May 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Lale Kostakoglu</investigator_full_name>
    <investigator_title>Chief of Nuclear Medicine and Molecular Imaging</investigator_title>
  </responsible_party>
  <keyword>68Ga- DOTATOC</keyword>
  <keyword>Diagnosis</keyword>
  <keyword>Somatostatin Receptor-Positive Neuroendocrine Tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Carcinoid Tumor</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Octreotide</mesh_term>
    <mesh_term>Edotreotide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

